Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The purpose of this trial is to determine 1. Disease stabilization/response rate after six 21-day cycles of ibrutinib 2. Remission status after six, twelve and 20 21-day cycles of ibrutinib
Critère d'inclusion
- Nodular Lymphocyte-Predominant Hodgkin's Lymphoma